Ocular Therapeutix, Inc. (OCUL) Financial Statements
Ocular Therapeutix, Inc. (OCUL) reported trailing twelve-month revenue of $52.1M (down 8.1% year on year) and net income of -$301.4M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$255.1M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
OCULOcular Therapeutix, Inc.Follow OCUL — free
—
Price chart with a free account
- Market cap
- 1.4B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.8 | 1.8 | 1.9 | 1.9 | 2.0 | 4.2 | 17.4 | 43.5 | 51.5 | 58.4 | 63.7 | 52.0 | 52.1 | |
| Gross profit | 0.7 | 1.4 | 1.4 | 1.5 | — | 1.9 | 15.3 | 39.1 | 47.0 | 53.2 | 58.1 | 45.4 | 45.3 | |
| Research & development | 18.9 | 26.6 | 27.1 | 30.9 | 36.9 | 41.1 | 28.7 | 50.1 | 53.5 | 61.1 | 127.6 | 197.1 | 223.5 | |
| Operating income | -27.1 | -38.2 | -43.3 | -61.9 | -59.1 | -85.8 | -62.8 | -78.0 | -78.7 | -82.4 | -171.8 | -270.0 | -313.9 | |
| Pre-tax income | -28.6 | -39.7 | -44.7 | 63.4 | 60.0 | -86.4 | -155.6 | -6.6 | -71.0 | -80.7 | -193.5 | -265.9 | -301.4 | |
| Income tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | |
| Net income | -28.6 | -39.7 | -44.7 | -63.4 | -60.0 | -86.4 | -155.6 | -6.6 | -71.0 | -80.7 | -193.5 | -265.9 | -301.4 | |
| Diluted EPS ($) | -2.69 | -1.71 | -1.80 | -2.20 | -1.57 | -1.91 | -2.56 | -0.98 | -0.97 | -1.02 | -1.22 | -1.42 | -1.34 | |
| Diluted shares (mn) | — | — | — | — | — | — | — | 82.2 | 82.6 | 85.6 | 158.3 | 187.2 | — |
USD millions · SEC XBRL
Ocular Therapeutix, Inc. — questions
- What is Ocular Therapeutix, Inc.'s revenue?
- $52.1M over the twelve months to 2026-06-30, down 8.1% year on year, from its 10-Q and 10-K filings.
- What is Ocular Therapeutix, Inc.'s net income?
- -$301.4M over the twelve months to 2026-06-30.
- What is Ocular Therapeutix, Inc.'s free cash flow?
- -$255.1M over the twelve months to 2026-06-30.
- What are Ocular Therapeutix, Inc.'s diluted earnings per share?
- $-1.34 over the twelve months to 2026-06-30.
Every figure on this page comes from Ocular Therapeutix, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.